{"title":"社交焦虑症的自我指导虚拟现实解决方案:随机对照研究的结果","authors":"Cameron Lacey , Chris Frampton , Ben Beaglehole","doi":"10.1016/j.jpsychires.2024.10.032","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The study examines the efficacy of a mobile application, oVRcome, which offers self-managed virtual reality exposure therapy combined with cognitive-behavioural techniques to treat social anxiety disorder.</div></div><div><h3>Methods</h3><div>A randomized controlled trial (RCT) was conducted over six weeks with a waitlist delayed treatment group and follow-ups at 12 and 18 weeks. Participants were adults living in New Zealand with moderate to severe social anxiety disorder, as measured by the Liebowitz Social Anxiety Scale (LSAS). The primary focus was on the change in LSAS scores from baseline to the sixth week. All analyses utilized the intention-to-treat data.</div></div><div><h3>Results</h3><div>Out of 126 randomized participants, 81 completed the six-week follow-up. The retention rate at week 6 was 67.5%. The reduction in LSAS scores was significantly greater in the active group compared to the waitlist delayed treatment group (active group mean = −35.7 [SD = 24.0]; waitlist group: mean = − 2.2 [SD = 13.5]; p < 0.001), for an effect size of 1.8.</div></div><div><h3>Conclusions</h3><div>The study demonstrates that oVRcome can effectively reduce social anxiety symptoms, offering a viable self-guided treatment option.</div></div><div><h3>Trial registry</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> ID NCT05576259.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"180 ","pages":"Pages 333-339"},"PeriodicalIF":3.7000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A self-guided virtual reality solution for social anxiety: Results from a randomized controlled study\",\"authors\":\"Cameron Lacey , Chris Frampton , Ben Beaglehole\",\"doi\":\"10.1016/j.jpsychires.2024.10.032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>The study examines the efficacy of a mobile application, oVRcome, which offers self-managed virtual reality exposure therapy combined with cognitive-behavioural techniques to treat social anxiety disorder.</div></div><div><h3>Methods</h3><div>A randomized controlled trial (RCT) was conducted over six weeks with a waitlist delayed treatment group and follow-ups at 12 and 18 weeks. Participants were adults living in New Zealand with moderate to severe social anxiety disorder, as measured by the Liebowitz Social Anxiety Scale (LSAS). The primary focus was on the change in LSAS scores from baseline to the sixth week. All analyses utilized the intention-to-treat data.</div></div><div><h3>Results</h3><div>Out of 126 randomized participants, 81 completed the six-week follow-up. The retention rate at week 6 was 67.5%. The reduction in LSAS scores was significantly greater in the active group compared to the waitlist delayed treatment group (active group mean = −35.7 [SD = 24.0]; waitlist group: mean = − 2.2 [SD = 13.5]; p < 0.001), for an effect size of 1.8.</div></div><div><h3>Conclusions</h3><div>The study demonstrates that oVRcome can effectively reduce social anxiety symptoms, offering a viable self-guided treatment option.</div></div><div><h3>Trial registry</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> ID NCT05576259.</div></div>\",\"PeriodicalId\":16868,\"journal\":{\"name\":\"Journal of psychiatric research\",\"volume\":\"180 \",\"pages\":\"Pages 333-339\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of psychiatric research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0022395624006174\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of psychiatric research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022395624006174","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
A self-guided virtual reality solution for social anxiety: Results from a randomized controlled study
Objective
The study examines the efficacy of a mobile application, oVRcome, which offers self-managed virtual reality exposure therapy combined with cognitive-behavioural techniques to treat social anxiety disorder.
Methods
A randomized controlled trial (RCT) was conducted over six weeks with a waitlist delayed treatment group and follow-ups at 12 and 18 weeks. Participants were adults living in New Zealand with moderate to severe social anxiety disorder, as measured by the Liebowitz Social Anxiety Scale (LSAS). The primary focus was on the change in LSAS scores from baseline to the sixth week. All analyses utilized the intention-to-treat data.
Results
Out of 126 randomized participants, 81 completed the six-week follow-up. The retention rate at week 6 was 67.5%. The reduction in LSAS scores was significantly greater in the active group compared to the waitlist delayed treatment group (active group mean = −35.7 [SD = 24.0]; waitlist group: mean = − 2.2 [SD = 13.5]; p < 0.001), for an effect size of 1.8.
Conclusions
The study demonstrates that oVRcome can effectively reduce social anxiety symptoms, offering a viable self-guided treatment option.
期刊介绍:
Founded in 1961 to report on the latest work in psychiatry and cognate disciplines, the Journal of Psychiatric Research is dedicated to innovative and timely studies of four important areas of research:
(1) clinical studies of all disciplines relating to psychiatric illness, as well as normal human behaviour, including biochemical, physiological, genetic, environmental, social, psychological and epidemiological factors;
(2) basic studies pertaining to psychiatry in such fields as neuropsychopharmacology, neuroendocrinology, electrophysiology, genetics, experimental psychology and epidemiology;
(3) the growing application of clinical laboratory techniques in psychiatry, including imagery and spectroscopy of the brain, molecular biology and computer sciences;